Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders
- PMID: 23736534
- DOI: 10.1093/eurjhf/hft088
Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders
Abstract
Aims: MicroRNAs (miRNAs) play an important role in the pathogenesis of structural alterations of the failing heart through their ability to regulate negatively the expression levels of genes that govern the process of adaptive and maladaptive cardiac remodelling. We studied whether LV reverse remodelling after CRT was associated with changes of circulating miRNAs in patients with heart failure (HF) and dyssynchrony.
Methods and results: A prospective, non-randomized self-control trial was performed in 81 patients with HF eligible for CRT. At baseline, to select the HF miRNA profile, we evaluated the expression of 84 miRNAs (implicated in the pathogenesis of structural alterations of the failing heart) in three groups of patients: healthy subjects (healthy group, n = 15); patients with HF (HF group, n = 81); and patients without HF matched for age, sex, and concomitant disease with HF patients (control group, n = 60). At 12 months, the selected miRNA profile was evaluated in plasma from responder (n = 55) and non-responder HF patients (n = 26) to CRT. In the test cohort, the HF patients were characterized by lower expression of 48 miRNAs (all P < 0.04) as compared with healthy subjects. In the validation cohort, the HF patients were characterized by lower expression of 24 miRNAs (all P < 0.03) as compared with control patients. At 12 months, 55 patients (68%) were considered responders and 26 non-responders to CRT (32%). Responders showed an increase in expression of 19 miRNAs (all P < 0.03) compared with baseline expression, whereas in the non-responders we observed an increase of six miRNAs (all P < 0.05) compared with baseline expression. At follow-up, miRNAs were differentially expressed between responders and non-responders. The responders were characterized by higher expression of five miRNAs (miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p; P < 0.01 for all) as compared with non-responders.
Conclusions: In responders, reverse remodelling is associated with favourable changes in miRNAs that regulate cardiac fibrosis, apoptosis, and hypertrophy.
Keywords: Cardiac resynchronization therapy; Heart failure; MicroRNAs.
Similar articles
-
Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure.Int J Cardiol. 2011 Dec 15;153(3):306-10. doi: 10.1016/j.ijcard.2010.08.048. Epub 2010 Sep 21. Int J Cardiol. 2011. PMID: 20863582
-
Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders.J Am Coll Cardiol. 2008 Jan 15;51(2):129-36. doi: 10.1016/j.jacc.2007.07.087. J Am Coll Cardiol. 2008. PMID: 18191736
-
Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.Eur J Heart Fail. 2012 Jan;14(1):74-81. doi: 10.1093/eurjhf/hfr151. Epub 2011 Nov 16. Eur J Heart Fail. 2012. PMID: 22089058 Clinical Trial.
-
Functional role of miRNA in cardiac resynchronization therapy.Pharmacogenomics. 2014 Jun;15(8):1159-68. doi: 10.2217/pgs.14.76. Pharmacogenomics. 2014. PMID: 25084208 Review.
-
Role of microRNAs in cardiac remodeling and heart failure.Cardiovasc Drugs Ther. 2011 Apr;25(2):171-82. doi: 10.1007/s10557-011-6289-5. Cardiovasc Drugs Ther. 2011. PMID: 21431305 Review.
Cited by
-
Reactive Oxygen Species, Endoplasmic Reticulum Stress and Mitochondrial Dysfunction: The Link with Cardiac Arrhythmogenesis.Front Physiol. 2016 Aug 3;7:313. doi: 10.3389/fphys.2016.00313. eCollection 2016. Front Physiol. 2016. PMID: 27536244 Free PMC article. Review.
-
Role of Selected miRNAs as Diagnostic and Prognostic Biomarkers in Cardiovascular Diseases, Including Coronary Artery Disease, Myocardial Infarction and Atherosclerosis.J Cardiovasc Dev Dis. 2021 Feb 19;8(2):22. doi: 10.3390/jcdd8020022. J Cardiovasc Dev Dis. 2021. PMID: 33669699 Free PMC article. Review.
-
Trajectory change of left ventricular ejection fraction after rhythm control for atrial fibrillation in heart failure.ESC Heart Fail. 2024 Apr;11(2):681-691. doi: 10.1002/ehf2.14590. Epub 2023 Dec 14. ESC Heart Fail. 2024. PMID: 38097279 Free PMC article.
-
AMD Genomics: Non-Coding RNAs as Biomarkers and Therapeutic Targets.J Clin Med. 2022 Mar 9;11(6):1484. doi: 10.3390/jcm11061484. J Clin Med. 2022. PMID: 35329812 Free PMC article. Review.
-
Non-coding RNAs: Important participants in cardiac fibrosis.Front Cardiovasc Med. 2022 Jul 28;9:937995. doi: 10.3389/fcvm.2022.937995. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35966549 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous